Brief: Precision Biosciences - Extended Cash Runway Through End Of 2025
07/11/2023 12:16
Nov 7 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES INC - EXTENDED CASH RUNWAY THROUGH
END OF
2025
* PRECISION BIOSCIENCES INC - TOTAL REVENUE FOR QUARTER
ENDED SEPT
30, 2023 $13.1 MILLION, VERSUS $7.4 MILLION FOR SAME PERIOD IN
2022
* PRECISION BIOSCIENCES INC - QTRLY NET LOSS WAS $0.07 PER
SHARE
* PRECISION BIOSCIENCES - AS OF SEPTEMBER 30, 2023,
PRECISION HAD
APPROXIMATELY $122.2 MILLION IN CASH AND CASH EQUIVALENTS
Source text for Eikon: ID:nBw1twBMva
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing